Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS®) in the Swedish COAST-study

European Neuropsychopharmacology

Volumn 23, Issue 12, 2013, Pages 1754-1762

  Brain, Cecilia ^a,b   Allerby, Katarina ^b   Sameby, Birgitta ^b   Quinlan, Patrick ^a,b   Joas, Erik ^a   Karilampi, Ulla ^b   Lindström, Eva ^c   Eberhard, Jonas ^d   Burns, Tom ^e   Waern, Margda ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adherence; Antipsychotics; Drug Attitude Inventory; Medication Event Monitoring System; Predictors; Schizophrenia

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COGNITION; DRUG ATTITUDE INVENTORY; DRUG MONITORING; DSM-IV; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONITOR; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY;

ADHERENCE; ANTIPSYCHOTICS; DRUG ATTITUDE INVENTORY; MEDICATION EVENT MONITORING SYSTEM; PREDICTORS; SCHIZOPHRENIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; ATTITUDE TO HEALTH; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MICRO-ELECTRICAL-MECHANICAL SYSTEMS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SWEDEN; YOUNG ADULT;

EID: 84887608510     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.09.001     Document Type: Article

References (50)

1. Amador X.F., Strauss D.H., Yale S.A., Flaum M.M., Endicott J., Gorman J.M. Assessment of insight in psychosis. Am. J. Psychiatry 1993, 150:873-879.
2. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162:441-449.
3. Cornblatt B.A., Risch N.J., Faris G., Friedman D., Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 1988, 26:223-238.
4. Day J.C., Bentall R.P., Roberts C., Randall F., Rogers A., Cattell D., Healy D., Rae P., Power C. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch. Gen. Psychiatry 2005, 62:717-724.
5. De Hert M., Yu W., Detraux J., Sweers K., van Winkel R., Correll C.U. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012, 26:733-759.
6. Diaz E., Neuse E., Sullivan M.C., Pearsall H.R., Woods S.W. Adherence to conventional and atypical antipsychotics after hospital discharge. J. Clin. Psychiatry 2004, 65:354-360.
7. Dolder C.R., Lacro J.P., Dunn L.B., Jeste D.V. Antipsychotic medication adherence: is there a difference between typical and atypical agents?. Am. J. Psychiatry 2002, 159:103-108.
8. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 1976, 33:766-771.
9. Gaebel W., Riesbeck M., von Wilmsdorff M., Burns T., Derks E.M., Kahn R.S., Rossler W., Fleischhacker W.W. Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur. Neuropsychopharmacol. 2010, 20:310-316.
10. Gold J.M., Carpenter C., Randolph C., Goldberg T.E., Weinberger D.R. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch. Gen. Psychiatry 1997, 54:159-165.
11. 1976, US Department of Health Education, a.W., Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville. W. Guy (Ed.).
12. Heaton R.K. Wisconsin Card Sorting Test manual: Revised and Expanded 1993, (S.l.).
13. Higashi K., Medic G., Littlewood K.J., Diez T., Granström O., De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther. Adv. Psychopharmacol. 2013, 3:200-218.
14. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med. 1983, 13:177-183.
15. Hosmer D.W., Lemeshow S. Applied Logistic Regression 2000, Wiley-Interscience.
16. Jeste S.D., Patterson T.L., Palmer B.W., Dolder C.R., Goldman S., Jeste D.V. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr. Res. 2003, 63:49-58.
17. Jonsdottir H., Opjordsmoen S., Birkenaes A.B., Simonsen C., Engh J.A., Ringen P.A., Vaskinn A., Friis S., Sundet K., Andreassen O.A. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr. Scand. 2013, 127:23-33.
18. Karilampi U., Helldin L., Archer T. Cognition and global assessment of functioning in male and female outpatients with schizophrenia spectrum disorders. J. Nerv. Ment. Dis. 2011, 199:445-448.
19. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
20. Kikkert M.J., Koeter M.W., Dekker J.J., Burti L., Robson D., Puschner B., Schene A.H. The predictive validity of subjective adherence measures in patients with schizophrenia. Int. J. Methods Psychiatr. Res. 2011, 20:73-81.
21. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 2002, 63:892-909.
22. Lepage M., Bodnar M., Joober R., Malla A. Is there an association between neurocognitive performance and medication adherence in first episode psychosis?. Early Interv. Psychiatry 2010, 4:189-195.
23. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lassig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013.
24. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
25. Lincoln T.M., Lullmann E., Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophr. Bull. 2007, 33:1324-1342.
26. Lindstrom E., Eriksson L., Levander S. Suicides during 7 years among a catchment area cohort of patients with psychoses. Nord. J. Psychiatry 2012, 66:8-13.
27. Lindstrom E., Lewander T., Malm U., Malt U.F., Lublin H., Ahlfors U.G. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord. J. Psychiatry 2001, 55(Suppl. 44):5-69.
28. Maeda K., Kasai K., Watanabe A., Henomatsu K., Rogers M.A., Kato N. Effect of subjective reasoning and neurocognition on medication adherence for persons with schizophrenia. Psychiatr. Serv. 2006, 57:1203-1205.
29. Menzin J., Boulanger L., Friedman M., Mackell J., Lloyd J.R. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr. Serv. 2003, 54:719-723.
30. Mingrone C., Rocca P., Castagna F., Montemagni C., Sigaudo M., Scalese M., Rocca G., Bogetto F. Insight in stable schizophrenia: relations with psychopathology and cognition. Compr. Psychiatry 2013, 54:484-492.
31. Morosini P.L., Magliano L., Brambilla L., Ugolini S., Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 2000, 101:323-329.
32. Nakonezny P.A., Byerly M.J., Rush A.J. Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity. Psychiatry Res. 2008, 157:259-263.
33. Nielsen R.E., Lindstrom E., Nielsen J., Levander S. DAI-10 is as good as DAI-30 in schizophrenia. Eur. Neuropsychopharmacol. 2012, 22:747-750.
34. Nose M., Barbui C., Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol. Med. 2003, 33:1149-1160.
35. Perkins D.O., Gu H., Weiden P.J., McEvoy J.P., Hamer R.M., Lieberman J.A. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry 2008, 69:106-113.
36. Reitan R.M. Validity of the Trailmaking Test as an indication of organic brain damage. Percept. Mot. Skills 1958, 8:271-276.
37. ®) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr. Res. 2007, 90:229-237.
38. Rey A. L'examen clinique en psychologie 1964, Presses universitaires de France, Paris.
39. Rosenheck R., Chang S., Choe Y., Cramer J., Xu W., Thomas J., Henderson W., Charney D. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J. Clin. Psychiatry 2000, 61:382-386.
40. Ruscher S.M., de Wit R., Mazmanian D. Psychiatric patients' attitudes about medication and factors affecting noncompliance. Psychiatr. Serv. 1997, 48:82-85.
41. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003, 29:15-31.
42. Sun S.X., Liu G.G., Christensen D.B., Fu A.Z. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr. Med. Res. Opin. 2007, 23:2305-2312.
43. Tiihonen J., Haukka J., Taylor M., Haddad P.M., Patel M.X., Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American. J. Psychiatry 2011, 168:603-609.
44. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Mandl R.C., Collins D.L., Evans A.C., Kahn R.S. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007, 32:2057-2066.
45. Velligan D.I., Lam Y.W.F., Glahn D.C., Barrett J.A., Maples N.J., Ereshefsky L., Miller A.L. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophrenia. Bull. 2006, 32:724-742.
46. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009, 70(Suppl. 4):1-46. Expert Consensus Panel on Adherence Problems in, S., Persistent Mental, I., (quiz 47-48).
47. Wechsler D. Wechsler Adult Intelligence Scale - Revised 1981, The Psychological Corporation, New York.
48. Weiden P.J., Mackell J.A., McDonnell D.D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr. Res. 2004, 66:51-57.
49. Yang J., Ko Y.-H., Paik J.-W., Lee M.-S., Han C., Joe S.-H., Jung I.-K., Jung H.-G., Kim S.-H. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr. Res. 2012, 134:226-231.
50. Zygmunt A., Olfson M., Boyer C.A., Mechanic D. Interventions to improve medication adherence in schizophrenia. Am. J. Psychiatry 2002, 159:1653-1664.